Cost Effectiveness of Different Central Venous Approaches for Port Placement and Use in Adult Oncology Patients: Evidence From a Randomized Three-Arm Trial
Authors:
- Roberto BiffiRBRoberto Biffi
- Simonetta PozziSPSimonetta Pozzi
- Guido BonomoGBGuido Bonomo
- Paolo Della VignaPVPaolo Della Vigna
- Lorenzo MonfardiniLorenzo Monfardini
- Davide RadiceDRDavide Radice
- Nicole RotmenszNRNicole Rotmensz
- Maria Giulia ZampinoMZMaria Giulia Zampino
- Nicola FazioNFNicola Fazio
- Franco OrsiFOFranco Orsi
- 20 May 2014
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (12) , 3725-3731
Abstract
No randomized trials have so far investigated the cost effectiveness of different methods for implantation and use of central venous ports in oncology patients. Overall, 403 patients eligible for receiving intravenous chemotherapy for solid tumours were randomly assigned to implantation of a single type of port, either through a percutaneous landmark access to the internal jugular vein, an ultrasound (US)-guided access to the subclavian vein, or a surgical cut-down access through the cephalic vein at the deltoid-pectoralis groove. Insertion and maintenance costs were estimated by obtaining the charges for an average implant and use, while the costs of the management of complications were analytically assessed. The total cost was defined as the purchase cost plus the insertion cost plus the maintenance cost plus the cost of treatment of the complications, if any. A total of 401 patients were evaluable-132 with the internal jugular vein, 136 with the subclavian vein and 133 with the cephalic vein access. No differences were found for the rate of early complications. The US-guided subclavian insertion site had significantly lower failures. Infections occurred in 1, 3, and 3 patients (internal jugular, subclavian, and cephalic access, respectively; p = 0.464), whereas venous thrombosis was observed in 15, 8, and 11 patients, respectively (p = 0.272). Mean cost for purchase, implantation, diagnosis and treatment of complications in each patient was 2,167.85 for subclavian US-guided, 2,335.87 for cephalic, and 2,384.10 for internal jugular access, respectively (p = 0.0001). US real-time guidance to the subclavian vein resulted in the most cost-effective method of central venous port placement and use.Keywords
This publication has 24 references indexed in Scilit:
- No impact of central venous insertion site on oncology patients’ quality of life and psychological distress. A randomized three-arm trialSupportive Care in Cancer, 2010
- Cost-effectiveness Analysis of Implantable Venous Access Device Insertion Using Interventional Radiologic versus Conventional Operating Room Methods in Pediatric Patients with CancerJournal of Vascular and Interventional Radiology, 2010
- Outcomes of surgical and radiologic placed implantable central venous access portsThe American Journal of Surgery, 2009
- An 11-year retrospective study of totally implanted central venous access ports: Complications and patient satisfactionEuropean Journal of Surgical Oncology, 2009
- Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trialAnnals of Oncology, 2009
- Vascular Access in Oncology PatientsCA: A Cancer Journal for Clinicians, 2008
- Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trialsStatistics in Medicine, 2005
- Radiological and surgical placement of port devices: a 4-year institutional analysis of procedure performance, quality of life and cost in breast cancer patientsBreast Cancer Research and Treatment, 2005
- Totally implantable central venous access ports for long-term chemotherapy A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 daysAnnals of Oncology, 1998
- Long-term, totally implantable central venous access ports connected to a Groshong atheter for chemotherapy of solid tumours: Experience from 178 cases using a single type of deviceEuropean Journal of Cancer, 1997